Plasma proteins as prognostic biomarkers in radiotherapy treated head and neck cancer patients
| Autor: | Lise Saksø Mortensen, Brita Singers Sørensen, Jan Alsner, Jens Overgaard, Line Brøndum, Jesper Grau Eriksen, Kasper Toustrup |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Eotaxin medicine.medical_specialty Pathology medicine.medical_treatment R895-920 Prognostic Article 03 medical and health sciences Medical physics. Medical radiology. Nuclear medicine 0302 clinical medicine Immune system Downregulation and upregulation Internal medicine medicine Radiology Nuclear Medicine and imaging Immune response Head and neck cancer Hypoxia RC254-282 Tumor microenvironment business.industry Cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Blood proteins Radiation therapy 030104 developmental biology 030220 oncology & carcinogenesis business Biomarkers Circulating proteins |
| Zdroj: | Brøndum, L, Eriksen, J G, Singers Sørensen, B, Mortensen, L S, Toustrup, K, Overgaard, J & Alsner, J 2017, ' Plasma proteins as prognostic biomarkers in radiotherapy treated head and neck cancer patients ', Clinical and Translational Radiation Oncology, vol. 2, pp. 46-52 . https://doi.org/10.1016/j.ctro.2017.01.001 Clinical and Translational Radiation Oncology, Vol 2, Iss C, Pp 46-52 (2017) Clinical and Translational Radiation Oncology |
| DOI: | 10.1016/j.ctro.2017.01.001 |
| Popis: | Background: Blood-based protein biomarkers can be a useful tool as pre-treatment prognostic markers, as they can reflect both variations in the tumor microenvironment and the host immune response. We investigated the influence of a panel of plasma proteins for the development of any failure defined as recurrent disease in the T-, N-, or M-site in HNSCC.Methods: We used a multiplex bead-based approach to analyze 19 proteins in 86 HNSCC patients and 15 healthy controls. We evaluated the associations between the biomarkers, loco-regional failure, failure in the T-, N-, or M-site, overall survival (OS), p16 status, and hypoxia.Results: In 41 p16 positive oropharynx cancer patients we identified a profile of biomarkers consisting of upregulation of IL-2, IL-4, IL-6, IL-8, eotaxin, GRO-a, and VEGF and downregulation of VEGFR-1 and VEGFR-2 with a significantly reduced risk of failure (p < 0.01). None of the individual proteins were associated with outcome.Conclusion: The identified plasma profile potentially reflects an activated immune response in a subgroup of the p16 positive patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|